US Stock Insider Trading | Compass Therapeutics disclosed 1 insider transaction on February 10

K-LinePoet · 2026-02-20T14:51:34+00:00

Compass Therapeutics disclosed on February 10, 2026, that Director Schuetz Thomas J. sold 36,700 shares on February 8 at a price of $6.52 per share. Recent insider trading activities include buy and sell transactions by other directors and executives, indicating active stock trading. The company focuses on developing immunotherapies for cancer.

K-LinePoet

2026-02-20 14:51:34

Abstract generation in progress

On February 10, 2026, Compass Therapeutics (CMPX) disclosed one insider transaction. Director Schuetz Thomas J. sold 36,700 shares on February 8, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 10, 2026	Director	Schuetz Thomas J.	February 8, 2026	Sell	36,700	6.52	239,200
January 12, 2026	Director	Schuetz Thomas J.	January 9, 2026	Sell	46,800	5.35	250,300
January 5, 2026	Executive	Shin Barry	January 2, 2026	Buy	125,000	5.17	646,300
January 5, 2026	Director	Schuetz Thomas J.	January 2, 2026	Buy	250,000	5.17	1,292,500
January 5, 2026	Executive	Anderman Jonathan	January 2, 2026	Buy	150,000	5.17	775,500
January 5, 2026	Executive	Lerner Neil	January 2, 2026	Buy	62,500	5.17	323,100
November 18, 2025	Director	Schuetz Thomas J.	November 16, 2025	Sell	44,000	4.83	212,600
May 27, 2025	Director	Schuetz Thomas J.	May 27, 2025	Buy	10,000	2.11	21,100
April 11, 2025	Shareholder with >10%	GORDON CARL L., ORBIMED ADVISORS LLC	April 9, 2025	Sell	7,142,900	1.59	11,357,100
April 8, 2025	Executive	Anderman Jonathan	April 7, 2025	Buy	20,000	1.54	30,800

[Company Profile]

Compass Therapeutics, Inc. was originally incorporated on March 20, 2018, in Delaware under the name Olivia Ventures, Inc. On June 17, 2020, the company changed its name to Compass Therapeutics, Inc. The company is a clinical-stage biopharmaceutical company developing proprietary antibody therapies aimed at harnessing the immune system to treat solid tumors and hematologic malignancies. Its immuno-oncology pipeline includes clinical-stage monoclonal antibodies and bispecific antibody combinations. These candidates are designed to address three key components necessary for effective anti-cancer immune responses: inducing a strong innate immune response; activating adaptive immunity; and mitigating tumor immune evasion and immune suppression mechanisms.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes